All Title Author
Keywords Abstract

Publish in OALib Journal
ISSN: 2333-9721
APC: Only $99


Relative Articles

Health  2024 

Factors of Adherence to Concurrent Tuberculosis Treatment and Antiretroviral Therapy among HIV-TB Co-Infected Individuals in the East Region, Cameroon in the COVID-19 Era: A Retrospective Cohort Study

DOI: 10.4236/health.2024.162012, PP. 131-147

Keywords: Factors of Adherence, Tuberculosis Treatment, Antiretroviral Therapy, HIV-TB Co-Infection, East Region, Cameroon

Full-Text   Cite this paper   Add to My Lib


Context/Objectives: Tuberculosis (TB) and HIV co-infection is a serious health problem in Cameroon. The problems associated with poor adherence to treatment are on the increase worldwide. This problem can be observed in all situations where patients are required to administer their own medication, whatever the type of illness. The general objective of this study was to assess the factors affecting adherence to treatment among HIV-TB co-infected patients in health facilities in the East Region in the COVID context. Method: A retrospective cohort study before and during COVID-19 was conducted in HIV care units in 13 health districts in the East Region of Cameroon. Data were collected using a questionnaire recorded in the Kobo Collect android application, analyzed using SPSS version 25 software and plotted using Excel. Results: The pre-COVID-19 cohort compared to the during-COVID-19 cohort had a 1.90 risk of not adhering to treatment (OR: 1.90, CI {1.90 - 3.37}) and the difference was statistically significant at the 5% level (p-value = 0.029). Frequency of adherence was 65.4% (140/214). Adherence before COVID-19 was 56.9% whereas during COVID-19, it was 74.3%. Conclusion: The implementation of targeted interventions in the COVID-19 context, using evidence-based data and integrating the individual needs of HIV-TB co-infected patients, improved adherence to concurrent anti-tuberculosis treatment and antiretroviral therapy during the COVID-19 Era.


[1]  WHO (2003) Adherence to Long-Term Therapies. Evidence for Action.
[2]  Allenet, B., Lehmann, A., Baudrant, M. and Gauchet, A. (2018) We Have to Stop Talking about “Non Compliant” Patients but Rather about Patients with Difficulties of Medication Adherence. Annales Pharmaceutiques Françaises, 76, 489-498.
[3]  Costedoat-Chalumeau, N., Tamirou, F. and Piette, J.-C. (2018) Treatment Adherence in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Time to Focus on This Important Issue. Rheumatology (Oxford, England), 57, 1507-1509.
[4]  WeLL (2018) L’adhésion thérapeutique et ses enjeux.
[5]  Ferreira, K.R., Orlandi, G.M., Silva, T.C., Bertolozzi, M.R., França, F.O.S. and Bender, A. (2018) Representations on Adherence to the Treatment of Multidrug-Resistant Tuberculosis. Revista da Escola de Enfermagem da USP, 52, e03412.
[6]  Kettani, A.E., Jebbar, S., Takourt, B., Maaloum, F., Diraa, O., Farouqi, B., Zerouali, K. and Filali, K.M.E. (2018) Co-infection VIH chez les tuberculeux suivis au service des maladies infectieuses du CHU Ibn Rochd-Casablanca. Pan African Medical Journal, 30, Article 276.
[7]  Noubom, M., Nembot, F.D., Donfack, H., Mfin, P.S. and Tchasse, F. (2013) Caracterisitiques des patients tuberculeux à l’ouest cameroun: 2000-2009. The Pan African Medical Journal, 16, Article 39.
[8]  Pefura Yone, E.W., Kuaban, C. and Kengne, A.P. (2012) HIV Testing, HIV Status and Outcomes of Treatment for Tuberculosis in a Major Diagnosis and Treatment Centre in Yaoundé, Cameroon: A Retrospective Cohort Study. BMC Infectious Diseases, 12, Article No. 190.
[9]  Diarra, S., Nasser, M.M., Konate, I., Dembele, M., Doucoure, D., Doumbıa, Y., Magassouba, O., Sogoba, D., Toloba, Y. and Dao, S. (2019) Co-infection VIH/Tuberculose dans le Service de Maladies Infectieuses du Centre Hospitalier Universitaire du Point G: Aspects épidémiocliniques et Thérapeutiques à propos de 48 Cas. Health Sciences and Disease, 20, 11-13.
[10]  Tékpa, G., Fikouma, V., Téngothi, R.M.M., Longo, J. de D., Woyengba, A.P.A. and Koffi, B. (2019) Aspects épidémiologiques et cliniques de la tuberculose en milieu hospitalier à Bangui. The Pan African Medical Journal, 33, Article 31.
[11]  Dabo, G., Bourama, K., Traoré, A.M., Mariko, M., Diabaté, K., Diarra, I.M., Diallo, K., Diallo, Y. and Minta, D.K. (2022) étude Epidémioclinique de la Tuberculose Pulmonaire chez les Personnes Vivant avec le VIH dans le District Sanitaire de Kolokani. Health Sciences and Disease, 23, 57-60.
[12]  Traoré, A. (2020) Impact de la Chimio Prophylaxie à l’Isoniazide sur la morbidité tuberculeuse et la mortalité chez les patients sous traitement antirétroviral au Centre de Santé de Référence de la Commune II du district de Bamako de 2016 à 2020. Master’s Thesis, Université des Sciences, des Techniques et des Technologies de Bamako, Bamako.
[13]  Traoré, F.A., Sako, F.B., Sylla, D., Bangoura, M., Kpamy, D.O., Traoré, M., Doumbouya, M. and Sangare, I. (2014) épidémiologie de la tuberculose pulmonaire bacillifère selon le statut VIH des patients suivis dans le service des maladies infectieuses de Conakry (Guinée). Bulletin de la Société de Pathologie Exotique, 107, 346-349.
[14]  Makougang Waffo, C.S. (2013) Coinfection VIH et Tuberculose Aspects épidémiologique, clinique et thérapeutique de la co-infection VIH/Tuberculose dans trois communes de Bamako. Presses Académiques Francophones, Saarbrücken.
[15]  Soumaré, D., Ouattara, K., Toloba, Y., Sissoko, B.F., Sidibé, F., Daou, S., et al. (2012) Co-infection TB/VIH: Tuberculose à l’ère du VIH en Afrique: Expérience du CHU du point-G. Revue des Maladies Respiratoires, 29, A197.
[16]  Agodokpessi, G., Ade, G., Ade, S., Wachinou, P., Affolabi, D., Anagonou, S., et al. (2012) évaluation de la prise en charge de la co-infection tuberculose et VIH à Cotonou, Bénin. Médecine et Maladies Infectieuses, 42, 561-566.
[17]  Mitku, A.A., Dessie, Z.G., Muluneh, E.K. and Workie, D.L. (2016) Prevalence and Associated Factors of TB/HIV Co-Infection among HIV Infected Patients in Amhara Region, Ethiopia. African Health Sciences, 16, 588-595.
[18]  Issoufi, M.I. (2008) Study of Adherence to ARV Treatment of Patients Followed at Gao Hospital. Doctoral Thesis, University of Bamako, Bamako.
[19]  Berkchi, M., Daoudi, M., Soualhi, M., Zahraoui, R., Marc, K., Benamor, J. and Bourkadi, J.E. (2020) Profil de la co-infection VIH et tuberculose. Revue des Maladies Respiratoires Actualités, 12, 162.
[20]  Agbota, G., Bonnet, M. and Lienhardt, C. (2022) Perspectives d’élimination de la tuberculose: La stratégie OMS à l’épreuve de la pandémie de COVID-19. Médecine et Maladies Infectieuses Formation, 1, 62-68.
[21]  Addo, J., Pearce, D., Metcalf, M., Lundquist, C., Thomas, G., Barros-Aguirre, D., Koh, G.C.K.W. and Strange, M. (2022) Living with Tuberculosis: A Qualitative Study of Patients’ Experiences with Disease and Treatment. BMC Public Health, 22, Article No. 1717.
[22]  Dje Bi, I.H., Anon, J.C., Yeo, L., Toh Bi, Y., Achi, V. and Meliane, N.S. (2019) Facteurs de mauvaise observance au traitement antituberculeux à Bouaké. Revue des Maladies Respiratoires, 36, A258-A259.
[23]  Yehia, B.R., Stewart, L., Momplaisir, F., Mody, A., Holtzman, C.W., Jacobs, L.M., Hines, J., Mounzer, K., Glanz, K., Metlay, J.P. and Shea, J.A. (2015) Barriers and Facilitators to Patient Retention in HIV Care. BMC Infectious Diseases, 15, Article No. 246.


comments powered by Disqus

Contact Us


WhatsApp +8615387084133

WeChat 1538708413